Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $194

نيوروكرين بيوساينسز

Neurocrine Biosciences, Inc.

NBIX

0.00

Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ: NBIX) with a Outperform and raises the price target from $185 to $194.